CD274 and lung carcinoma: PLK1i volasertib and WEE1i adavosertib have been shown to enhance response to anti‐PD‐1 agents in models of lung cancer by increasing PD‐L1 expression, activating interferon pathways and stimulating cytotoxic T cell infiltration, and our group observed a similar outcome with TTKi CFI‐402257 in a murine model of colon cancer.192, 232, 233